Galafold (Migalastat): Understanding Treatment for Fabry Disease

Galafold (migalastat hydrochloride) is an oral pharmacological chaperone therapy for Fabry disease, a rare X-linked lysosomal storage disorder caused by deficient alpha-galactosidase A (α-Gal A) enzyme activity. It is the first disease-modifying oral therapy for amenable GLA mutations.

Mechanism of Action

  • Migalastat selectively binds to specific mutant forms of α-Gal A, stabilizing their three-dimensional structure.
  • This prevents premature degradation in the endoplasmic reticulum, allowing properly folded enzyme to traffic to lysosomes.
  • In lysosomes, the stabilized enzyme cleaves accumulated globotriaosylceramide (Gb3 / GL-3), the pathogenic substrate.

Stabilizing and Increasing Enzyme Activity

  • Only amenable mutations (missense, some splicing variants) respond—~35–50% of GLA variants. Genetic testing with amenability assay is required before prescribing.
  • Increased residual enzyme activity reduces Gb3 accumulation in key tissues: kidneys, heart, skin, nervous system, GI tract.

Clinical Benefits

  • Reduces plasma and urine Gb3 (lyso-Gb3) levels.
  • Alleviates neuropathic pain, fatigue, GI symptoms (diarrhea, abdominal pain), angiokeratomas, hypohidrosis.
  • May slow eGFR decline, stabilize cardiac mass, reduce arrhythmia burden.
  • Improves patient-reported outcomes and quality of life.

Dosing & Administration

  • One 123 mg capsule orally every other day (q.o.d.).
  • Take on empty stomach: at least 2 hours after food and 2 hours before next meal (food reduces bioavailability ~40%).
  • No renal or hepatic dose adjustment needed.

Safety & Monitoring

  • Generally well-tolerated. Most common AEs: headache, nasopharyngitis, urinary tract infection, nausea, fever.
  • No black box warnings.
  • Monitor: kidney function (eGFR, proteinuria), cardiac (echo/MRI, ECG), lyso-Gb3 levels, symptom scores every 6–12 months.
  • Not a cure—chronic therapy required to maintain enzyme stabilization and substrate reduction.

Galafold represents a milestone for Fabry patients with amenable mutations: a convenient, oral, disease-modifying option that targets the root enzymatic defect. Early initiation maximizes organ protection and long-term outcomes.

Gum Disease - Related Articles